CagriSema: Novo's Answer to Tirzepatide

A once-weekly fixed-dose injectable combining cagrilintide (a long-acting amylin analogue) with semaglutide (the GLP-1 in Wegovy). Phase 3 REDEFINE-1/2 trials show ~22% mean weight loss — Novo Nordisk’s response to tirzepatide and retatrutide.

🔬 CagriSema bets that adding amylin to GLP-1 closes the gap to tirzepatide without needing the GIP receptor. The phase 3 readout came in below internal expectations — efficacy is real but the trial bar was higher.

Mean Body Weight
Loss (REDEFINE-1, 68wk)

GLP-1 + Amylin
Dual Mechanism

Once-Weekly
Subcutaneous Inj.

Mechanism of Action

How It Works

🧬

Cagrilintide (Amylin)

Long-acting amylin analogue. Slows gastric emptying, suppresses glucagon, drives early-meal satiety via amylin receptors in the area postrema and hypothalamus.

💉

Semaglutide (GLP-1)

Same molecule as Wegovy/Ozempic. Activates GLP-1 receptors — insulin secretion, slowed gastric emptying, central appetite suppression. Half-life ~165 hours.

🔁

Complementary Pathways

Amylin and GLP-1 act on overlapping but distinct CNS appetite circuits. Combination produces additive (not redundant) appetite suppression and gastric-emptying delay.

📅

Once-Weekly Fixed-Dose

Single injection containing both molecules. Highest tested dose: cagrilintide 2.4 mg + semaglutide 2.4 mg. Titrated over ~16 weeks.

Data

What the Data Shows

CagriSema 2.4/2.4 mg (REDEFINE-1, 68 wk)

Mean body weight loss vs placebo

22.7%

Semaglutide 2.4 mg Alone (Wegovy)

STEP-1 trial, 68 weeks

14.9%

Cagrilintide 2.4 mg Alone

Earlier phase 2 monotherapy data

~10.8%

Tirzepatide 15 mg (Zepbound, Comparator)

SURMOUNT-1, 72 weeks

~20.9%

Patients ≥20% Weight Loss (CagriSema)

REDEFINE-1

~40%

Bottom Line

Key Takeaways

✅ What We Know

Once-weekly fixed-dose injectable (cagrilintide + semaglutide)
Phase 3 REDEFINE-1: ~22.7% mean body weight loss at 68 weeks
Phase 3 REDEFINE-2 (T2D): ~15.7% weight loss + significant A1C reduction
Dual mechanism: GLP-1R + amylin receptor
FDA decision expected late 2026 / early 2027
Side-effect profile similar to high-dose semaglutide (GI predominantly)

⚠️ What We Don't Know

Whether the additional cagrilintide cost is justified vs upping semaglutide alone
Long-term cardiovascular outcomes — SELECT-style trial pending
Real-world durability of weight loss after cessation
Direct head-to-head vs retatrutide (no published trial)

FAQ

Frequently Asked Questions

What is CagriSema?

CagriSema is a once-weekly fixed-dose subcutaneous injection from Novo Nordisk combining cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 receptor agonist). It targets two appetite-regulating pathways simultaneously and is being developed for obesity and type 2 diabetes.

How much weight loss does CagriSema produce?

In phase 3 REDEFINE-1 (68 weeks, obesity without diabetes), CagriSema 2.4/2.4 mg produced ~22.7% mean body weight loss. In REDEFINE-2 (T2D), the figure was ~15.7% — diabetes typically blunts GLP-1 weight-loss response.

How does CagriSema compare to tirzepatide?

In cross-trial comparison, CagriSema (~22.7%) is roughly comparable to tirzepatide 15 mg (~20.9% in SURMOUNT-1). Mechanism differs — tirzepatide is GLP-1 + GIP, CagriSema is GLP-1 + amylin. No direct head-to-head trial has been published.

When will CagriSema be FDA-approved?

Novo Nordisk submitted regulatory filings after REDEFINE-1/2 readouts. FDA decision is expected late 2026 / early 2027. Approval is widely anticipated given the efficacy data.

What are the side effects?

Predominantly gastrointestinal — nausea, vomiting, diarrhea, constipation — typical of GLP-1s. Cagrilintide adds amylin-mediated GI delay, which can amplify early-meal fullness. Most events are mild-moderate and titration-related.